The Life Sciences team advised Calytrix Bio, Inc. (Calytrix) on its definitive agreement to be acquired by Eli Lilly and Company (Lilly). Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

Calytrix Bio is a privately held biotechnology company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms. The company’s initial focus is mCALR-driven essential thrombocythemia and myelofibrosis. Calytrix Bio’s lead preclinical program is a novel biparatopic antibody designed to deliver pan-mutant activity by targeting both Type 1 and Type 2 mCALR, with the goal of providing disease-modifying therapy with safety and convenience that support early intervention and long-term treatment.

The Goodwin team was led by Bill Collins, Sarah Solomon, Allison Nicklin, Wei Xu, Serene Qandil, Ben Rodrigues, Dan Karelitz, Chase Gorland, Grace Wirth, Qiuyu (Zoe) Li, Dasol Lee, Jennifer Ford, Timothy Holahan, Anna Shipley Roy, Susan Lee, Krupa Zachariah, Matt Wetzel, Dustin Schaefer, Deborah Birnbach, John Barker, Jacqueline Klosek, Jacob Osborne, Kuwabo O’Brien, Arman Oruc, and Nancy Urizar.

For more information on the deal, please read the press release.